SecBot SecBot
424B5 ·Filed Jul 14, 2026

ERAS

Erasca, Inc.
MIXED
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-303352
Notable filing: 424B5
Actionable Insight ◆ Mixed

The offering provides a substantial cash runway to fund pivotal trials for ERAS-0015 through key catalysts in 2027, including a potential registration-enabling NSCLC trial and Phase 3 PDAC trial. The 10% dilution is a near-term headwind, but the strong Phase 1 data and accelerated development plans could support the stock if data continues to impress. Monitor for further clinical updates and any insider selling post-lockup expiration (60 days).

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

ERAS drug pipeline →

ERAS-0015

◆ Mixed Named in this 424B5
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$21.26
T+0 close · Jul 14, 2026 · via day close
Latest settled
−27.28%
T+60 · $15.46
Vs SPY
−29.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $21.26entry
  2. T+1 · 4mo ago −10.54%α −9.99% · $19.02
  3. T+5 · 4mo ago −8.23%α −7.25% · $19.51
  4. T+20 · 3mo ago −12.61%α −14.95% · $18.58
  5. T+60 · 6w ago −27.28%α −29.81% · $15.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceeds of ~$516M to fund R&D for its RAS/MAPK pipeline. The filing also discloses encouraging updated Phase 1 data for lead candidate ERAS-0015, showing a 57% uORR8wk in 2L KRAS G12X PDAC at the 32mg RDE dose. The combination of dilutive financing and positive clinical data creates a mixed signal for the stock.

Key Facts

  • Offering of 31,428,572 shares at $17.50 per share, raising $550M in gross proceeds (~$516M net)
  • Underwriters have a 30-day option to purchase an additional 4,714,285 shares
  • Post-offering shares outstanding: 342,235,460 (or 346,949,745 if overallotment exercised)
  • New investors face immediate dilution of $14.84 per share (85% of offering price)
  • Net tangible book value increases from $1.27 to $2.66 per share post-offering
  • Updated Phase 1 data for ERAS-0015 shows 57% uORR8wk (N=7) at 32mg QD in 2L KRAS G12X PDAC
  • ERAS-0015 combination with panitumumab cleared first dose escalation cohort with no DLTs
  • Company plans to initiate potentially registration-enabling trial in NSCLC in H1 2027 and Phase 3 pivotal trial in PDAC in 2027
  • Proceeds to fund R&D, working capital, and potential in-licensing/acquisitions
  • $200M ATM facility with Jefferies remains available

Financial Impact

Gross proceeds of $550M ($516M net) from sale of 31.4M shares at $17.50; immediate dilution of $14.84 per share for new investors; post-offering cash position increases to ~$909.5M in net tangible book value

dilutioncashPositionsharesOutstanding

Risk Factors

  • Immediate and substantial dilution of 85% of offering price for new investors
  • Clinical-stage biotech with no approved products; ERAS-0015 data is preliminary and from small sample sizes
  • Potential for further dilution from $200M ATM facility and outstanding options (58.4M shares)
  • Competitive landscape for RAS/MAPK-targeted therapies is intense
  • One Grade 5 pneumonitis event reported in safety data raises toxicity concerns

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-303352
Document: d116467dexfilingfees.htm0001193125-26-303352
Document: 0001193125-26-303352-index-headers.html0001193125-26-303352
Document: 0001193125-26-303352-index.html0001193125-26-303352
Document: 0001193125-26-303352.txt0001193125-26-303352

Track record

26 reports on ERAS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026